Were Crystal Adam’s Tango Therapeutics (TNGX) share sales pre-planned under Rule 10b5-1?

Yes. The filing states that the transactions were executed under a Rule 10b5-1 trading plan adopted on October 27, 2025. Such plans schedule trades in advance, which can make the timing of sales less indicative of short-term views on the stock.

How significant is the 12,000-share sale by Tango Therapeutics (TNGX) executive Crystal Adam?

The sale involves 12,000 shares compared with 112,622 shares of common stock she still holds afterward. She also retains 460,500 stock options, so the disposition represents a relatively small portion of her overall economic exposure to Tango Therapeutics.

Tango Therapeutics (TNGX) R&D chief exercises options, sells 12,000 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tango Therapeutics, Inc. President of R&D Crystal Adam reported an option exercise and related stock sale. On March 25, 2026, she exercised stock options to acquire 12,000 shares of common stock at $5.20 per share, then sold 12,000 shares in open‑market transactions at a weighted‑average price of $20.11 per share.

These trades were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on October 27, 2025. After the transactions, she held 112,622 shares of common stock directly and 460,500 stock options, indicating the sale represents a relatively small portion of her overall position.

Insider Trade Summary 10b5-1

Net Seller: 12,000 shares ($241,320)

Net Sell 3 txns

Insider Crystal Adam

Role President, R&D

Sold 12,000 shs ($241K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	12,000	$0.00	--
Exercise	Common Stock	12,000	$5.20	$62K
Sale	Common Stock	12,000	$20.11	$241K

Holdings After Transaction: Stock Option (Right to Buy) — 460,500 shares (Direct); Common Stock — 124,622 shares (Direct)

Footnotes (1)

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

03/27/2026 - 08:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crystal Adam

(Last)

(First)

(Middle)

C/O TANGO THERAPEUTICS, INC.,

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON

MASSACHUSETTS

02215

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/25/2026		M⁽¹⁾		12,000	A	$5.2	124,622	D
Common Stock	03/25/2026		S⁽²⁾		12,000	D	$20.11⁽²⁾	112,622	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$5.2	03/25/2026		M⁽¹⁾			12,000	⁽³⁾	03/01/2033	Common Stock	12,000	$0	460,500	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

	/s/ Julie Fogarty, as attorney-in-fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Tango Therapeutics (TNGX) executive Crystal Adam report in this Form 4?

Crystal Adam reported exercising 12,000 stock options and selling 12,000 Tango Therapeutics common shares. The sale was executed at a weighted-average price of $20.11 per share, linked to options with a $5.20 exercise price, under a pre-arranged Rule 10b5-1 plan.

How many Tango Therapeutics (TNGX) shares did Crystal Adam sell and at what price?

She sold 12,000 shares of Tango Therapeutics common stock in open-market transactions. The weighted-average sale price was $20.11 per share, with individual trades ranging between $20.00 and $20.27, as disclosed in the Form 4 footnotes for this transaction.

What stock options did Crystal Adam exercise in the Tango Therapeutics (TNGX) filing?

She exercised stock options covering 12,000 shares of Tango Therapeutics common stock at an exercise price of $5.20 per share. These options are part of a grant vesting over four years, with 25% vesting on February 27, 2024 and the remainder monthly thereafter.

How many Tango Therapeutics (TNGX) shares and options does Crystal Adam hold after the transactions?

Following the reported transactions, she directly holds 112,622 shares of Tango Therapeutics common stock. She also holds 460,500 stock options, giving her a substantial remaining equity-linked interest in the company despite the 12,000-share sale.